Core Viewpoint - Micron Robotics-B (02252) has achieved a significant milestone with the approval of its bronchoscopic surgical robot, UniPathTM, by the National Medical Products Administration (NMPA), marking a breakthrough in the field of surgical robotics and expanding its product offerings to seven approved surgical robots [1] Group 1: Company Developments - The stock price of Micron Robotics-B surged by 13.58% to HKD 24.08, with a trading volume of HKD 109 million [1] - The approval of UniPathTM represents a comprehensive coverage of key technological pathways in minimally invasive diagnosis and treatment for domestic surgical robots [1] - Micron Robotics-B is now the first and only company globally to commercialize products across all five major categories of surgical robots [1] Group 2: Product Details - UniPathTM is a non-invasive robotic surgical platform that utilizes a highly flexible, ultra-thin snake-like robotic catheter to access hard-to-reach narrow lesions through natural body cavities [1] - The platform is significant for the early diagnosis and treatment of early-stage cancers, such as small nodules in the lungs [1]

本次独道获得NMPA批准，是本集团引领全球手术机器人领域技术与应用发展的里程碑式突破，也标志 着国产手术机器人在微无创诊疗关键技术路径上实现系统性全覆盖。至此，本集团在手术机器人领域获 批上市的产品数量增至7款，成为全球首家、也是目前唯一一家实现手术机器人"五大黄金赛道"全赛道 产品商业化上市的企业。 据介绍，最新获批的独道是一个无创经自然腔道机器人手术平台，其具有超柔顺，超纤细蛇形机器人导 管，可通过人体自然腔道，以无体表创伤的方式进入难以触及的狭窄病灶空间，对肺部微小结节等癌症 早期病变的早诊早治具有重要意义。 微创机器人-B(02252)涨超7%，截至发稿，涨7.64%，报22.58港元，成交额2045.01万港元。 消息面上，12月24日，微创机器人-B发布公告，由本集团自主研发的支气管镜手术机器人独道 UniPathTM电子支气管镜手术导航系统(独道)正式获得国家药品监督管理局(NMPA)批准。 ...

智通财经APP获悉，微创机器人-B(02252)涨超7%，截至发稿，涨7.64%，报22.58港元，成交额2045.01 万港元。 消息面上，12月24日，微创机器人-B发布公告，由本集团自主研发的支气管镜手术机器人独道 ®UniPathTM电子支气管镜手术导航系统(独道)正式获得国家药品监督管理局(NMPA)批准。 本次独道获得NMPA批准，是本集团引领全球手术机器人领域技术与应用发展的里程碑式突破，也标志 着国产手术机器人在微无创诊疗关键技术路径上实现系统性全覆盖。至此，本集团在手术机器人领域获 批上市的产品数量增至7 款，成为全球首家、也是目前唯一一家实现手术机器人"五大黄金赛道"全赛道 产品商业化上市的企业。 据介绍，最新获批的独道是一个无创经自然腔道机器人手术平台，其具有超柔顺，超纤细蛇形机器人导 管，可通过人体自然腔道，以无体表创伤的方式进入难以触及的狭窄病灶空间，对肺部微小结节等癌症 早期病变的早诊早治具有重要意义。 ...

Core Viewpoint - Shenzhen Precision Medical Technology Co., Ltd. is set to become the first domestic surgical robot company listed on the Hong Kong Stock Exchange, having passed the listing hearing on December 21, 2025 [2] Group 1: IPO Details - The company plans to issue up to 31.88 million new shares, with 49 shareholders converting 296 million shares into H-shares for circulation [3] - Joint sponsors for the IPO include Morgan Stanley and GF Securities [3] Group 2: Company Overview - Established in 2017, Precision Medical is the first in China and the second globally to have listing qualifications for multi-port, single-port, and natural orifice surgical robots [3] - The company focuses on the R&D, production, and sales of surgical robots and related instruments, covering various minimally invasive surgical needs across multiple departments [3] Group 3: Technological and Market Position - As of May 2025, the company holds over 800 global patents and patent applications, achieving self-controlled core technologies that break the long-standing overseas monopoly [3] - The products have been adopted in over 220 top-tier hospitals across 30 provinces in China, including renowned institutions like Peking University Third Hospital and Zhejiang University First Hospital [3] - Overseas revenue accounts for 40.60%, establishing a dual growth engine from domestic and international markets [3] Group 4: Financial Performance - The company demonstrates stable profitability, with gross margins of 59.30%, 61.30%, and 62.80% for the years 2023 to the first half of 2025, showing a steady upward trend [4] - In the first half of 2025, revenue reached 149 million yuan, indicating strong growth performance [4]

商业化装机方面，公司旗下各产品共完成商业化装机150余台。其中，图迈全球范围内的商业化装机量 已突破百台，该百台装机均已取得用户签署的装机验收报告。公司称，图迈成为首个实现百台商业化装 机的国产腔镜手术机器人，不仅证明其已具备行业基础设施级的系统可靠性与临床稳定性，也标志着其 在质量合规、生产工艺、工程验证、系统交付、临床适配及全流程保障能力等关键体系上实现了全面跃 升。 在国内市场，图迈在头部公立医院及高端非公立医院市场均取得突破性进展，装机医院中百强医院占比 已达到23%，三甲医院占比超过90%，图迈已逐步形成以临床价值驱动、专业能力沉淀为核心的高质量 装机格局。截至目前，图迈海外市场布局已广泛覆盖亚洲、欧洲、非洲、大洋洲、南美洲的40余个国家 和地区，获得当地顶级机构的认可，并已在15个国家实现"多台销售、多院装机"，实现在全球不同地域 成熟医疗体系内的常态化、网络化、规模化使用。 公司表示，这一里程碑式突破，不仅标志着国产手术机器人在微创与微无创诊疗关键技术路径上实现系 统性全覆盖，也意味着中国在该领域已无关键技术"空白"。在此基础上，一个由微创机器人持续构建， 以体系化创新为内核、以平台化能力输出为 ...

Core Viewpoint - The article emphasizes the importance of innovation in the medical device industry, particularly in the surgical stapler market, where a Chinese company, Tianchen Medical, is breaking the long-standing monopoly of international giants through self-innovation and a focus on affordability and accessibility [1][4]. Company Overview - Tianchen Medical, established in 2003, specializes in high-end surgical staplers and has developed a product system covering five categories across various fields such as cardiothoracic, gastrointestinal, and general surgery [1][6]. - In the first three quarters of the year, the company achieved revenue of 244 million yuan and a net profit of 71.95 million yuan, representing year-on-year growth of 20.66% and 68.29%, respectively [1]. Innovation and Product Development - The TST series stapler, designed for prolapse surgery, allows the procedure to be completed with a single device, significantly reducing operational difficulty and medical costs [2][6]. - Tianchen Medical employs a co-creation research and development model, involving frontline clinical doctors in the design process to address real clinical pain points [2][5]. Market Dynamics - The surgical stapler market was previously dominated by a few international giants, with prices around 20,000 yuan and profit margins exceeding 90%, making it unaffordable for many patients [4][7]. - The lack of effective competition led to a stagnation in innovation, with no core patent breakthroughs in nearly a decade [4]. Patent Strategy - Tianchen Medical has developed a "jungle-style" patent strategy to navigate the complex patent landscape dominated by international competitors, resulting in a robust intellectual property defense [5][6]. - As of mid-2025, the company holds 822 patents globally, including 565 invention patents, successfully breaking the long-standing intellectual property monopoly in the field [6]. Competitive Positioning - The company’s technology has reached parity with international giants, leading to a significant reduction in the price of staplers from nearly 20,000 yuan to about one-tenth of that, making technology more accessible [7]. - Tianchen Medical's self-developed laparoscopic stapler products are now competitive with international counterparts, reducing surgical trauma and enabling new surgical techniques [7]. Future Directions - The company is focusing on the next phase of development in surgical robotics, aiming to create an open, standardized intelligent surgical platform rather than a closed, high-cost system [8][9]. - This approach aims to enhance the accessibility and affordability of surgical robotics, contributing to a more sustainable and innovative medical environment [9].

Group 1 - The core viewpoint of the news is that MicroPort Robotics has received approval from the National Medical Products Administration (NMPA) for its self-developed bronchoscopic surgical robot, UniPathTM, marking a significant milestone in the field of surgical robotics and indicating comprehensive coverage of key technologies in minimally invasive diagnosis and treatment [1] - With this approval, the number of surgical robot products approved for market by the company has increased to seven, making it the first and only company globally to commercialize products across all five major categories of surgical robots [1] - The newly approved UniPathTM is a non-invasive robotic surgical platform that utilizes a highly flexible, slender robotic catheter to access hard-to-reach narrow lesions through natural body cavities, which is crucial for the early diagnosis and treatment of early-stage lung cancer [1] Group 2 - As a representative of natural orifice transluminal endoscopic surgery (NOTES) robots, the bronchoscopic surgical robot is seen as a key technological pathway for advancing minimally invasive surgery towards "less trauma and no external incisions" [2] - UniPathTM integrates critical technologies such as precise robotic control, flexible catheter navigation, intelligent path planning, and closed-loop control, providing a comprehensive solution for complex pulmonary anatomy [2] - The system enhances accessibility to fine bronchi and deep lung segments, supporting higher certainty in reaching and performing puncture and ablation operations on small lesions under dynamic breathing conditions, thereby continuously expanding the clinical application boundaries of bronchoscopic interventions [2]

作为经自然腔道手术机器人的典型代表，支气管镜手术机器人被视为推动微创外科向"更少创伤、无体 表切口"演进的重要技术路径，亦是近年来呼吸介入领域发展最快的智慧微创诊疗平台之一。 智通财经APP讯，微创机器人-B(02252)发布公告，由本集团自主研发的支气管镜手术机器人独道 ®UniPathTM电子支气管镜手术导航系统(独道)正式获得国家药品监督管理局(NMPA)批准。 本次独道获得NMPA批准，是本集团引领全球手术机器人领域技术与应用发展的里程碑式突破，也标志 着国产手术机器人在微无创诊疗关键技术路径上实现系统性全覆盖。至此，本集团在手术机器人领域获 批上市的产品数量增至7 款，成为全球首家、也是目前唯一一家实现手术机器人"五大黄金赛道"全赛道 产品商业化上市的企业。一个由本集团持续构建，以体系化创新为内核、以平台化能力输出为支撑，兼 具系统完整性、技术纵深与可持续演进能力的国产手术机器人生态体系，正加速成型并迈入规模化发展 阶段。 最新获批的独道是一个无创经自然腔道机器人手术平台，其具有超柔顺，超纤细蛇形机器人导管，可通 过人体自然腔道，以无体表创伤的方式进入难以触及的狭窄病灶空间，对肺部微小结节等癌症早期 ...

Core Insights - The company, MicroPort Robotics-B (02252.HK), has received approval from the National Medical Products Administration (NMPA) for its self-developed bronchoscopic surgical robot, UniPathTM, marking a significant milestone in the field of surgical robotics [1] - This approval increases the number of products approved for market by the company in the surgical robotics sector to seven, making it the first and only company globally to commercialize products across all five major categories of surgical robots [1] - The newly approved UniPathTM is a non-invasive robotic surgical platform that utilizes a highly flexible, slender robotic catheter to access hard-to-reach areas within the body through natural orifices, which is crucial for early diagnosis and treatment of small lung nodules and early-stage cancers [1] Industry Insights - As a representative of natural orifice surgical robots, bronchoscopic surgical robots are seen as a key technological pathway for advancing minimally invasive surgery towards "less trauma and no external incisions" [2] - UniPathTM integrates critical technologies such as precise robotic control, flexible catheter navigation, intelligent path planning, and closed-loop control, providing a comprehensive solution for complex pulmonary anatomy [2] - The system enhances accessibility to fine bronchi and deep lung segments, supporting higher certainty in reaching and performing puncture and ablation operations on small lesions under dynamic respiratory conditions, thereby expanding the clinical application boundaries of bronchoscopic interventions [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2252） 自願性公告 獨道電子支氣管鏡手術導航系統 獲得國家藥品監督管理局註冊批准 本公告由上海微創醫療機器人（集團）股份有限公司（「本公司」與其附屬公司合 稱「本集團」）自願作出，以向本公司股東及潛在投資者提供有關本集團的最新 業務進展情況。 本公司董事會（「董事會」）欣然宣佈由本集團自主研發的支氣管鏡手術機器人 獨道®UniPathTM電子支氣管鏡手術導航系統（「獨道」）正式獲得國家藥品監督管 理局（「NMPA」）批准。 對本公司的影響 本次獨道獲得NMPA批准，是本集團引領全球手術機器人領域技術與應用發展 的里程碑式突破，也標誌著國產手術機器人在微無創診療關鍵技術路徑上實 現系統性全覆蓋。至此，本集團在手術機器人領域獲批上市的產品數量增至7 款，成為全球首家、也是目前唯一一家實現手術機器人「五大黃金賽道」全賽道 產品商業化上市的企業。一個由 ...